Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction.

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Inclusion Criteria:

• Age ≥ 18 and < 75 years old when entering the rheumatology department
• Hospitalization in the rheumatology department
• Patient with acute non-traumatic musculoskeletal disease
• Patient not taking grade III opioid treatment
• Patient affiliated to a social security scheme
• Patient having read and understood the information letter and signed the consent form
• Patient present on a day which the pharmacy intern is present

Exclusion Criteria:

• Presence of cancer, fibromyalgia, already diagnosed at inclusion
• Patient does not understand French
• Patient with Current or past opioid addiction
• Person deprived of liberty by administrative or judicial decision